Risk of Prostate Cancer-Specific Mortality Following Biochemical Recurrence After Radical Prostatectomy

Freedland, Stephen J.; Humphreys, Elizabeth B.; Mangold, Leslie A.; Eisenberger, Mario A.; Dorey, Frederick J.; Walsh, Patrick C.; Partin, Alan W.

doi:10.1016/s0022-5347(05)00388-5

Cited by 183 publications

(269 citation statements)

References 31 publications

Supporting

Mentioning

255

Contrasting

Unclassified

Order By: Relevance

“…Among the roughly one-third of men with PCa in the United States who undergo RP [20], some will experience a recurrence, of which a proportion will progress and be at risk for death [21]. PSA kinetics can help identify these patients [22] but often involve multiple PSA measurements that can result in a delay of secondary therapy. Risk assessment tools that can accurately predict cancer recurrence and progression would allow a more timely institution of additional treatments that might be beneficial for selected patients [23][24][25].…”

Section: Discussionmentioning

confidence: 99%

Multi-institutional Validation of the CAPRA-S Score to Predict Disease Recurrence and Mortality After Radical Prostatectomy

et al. 2014

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Multi-institutional Validation of the CAPRA-S Score to Predict Disease Recurrence and Mortality After Radical Prostatectomy

et al. 2014

View full text Add to dashboard Cite

“…Before understanding the potential impact of salvage therapies on PCa, it is important to review the natural history of recurrent PCa. To accomplish this, Freedland and colleagues retrospectively assessed 379 men with BCR after RP who were managed expectantly with ADT for clinical metastasis [18]. Most men lived >15 yr after BCR, and only some men progressed to clinical metastasis or death.…”

Section: 2mentioning

confidence: 99%

“…Although previous studies have shown that longer times to BCR after RP are associated with a greater likelihood of localized disease and decreased PCa mortality [18], more recent studies have failed to find this association between time to BCR and death from PCa [21]. Studies have reported that a longer PSA DT is associated with a decreased likelihood of PCa progression, the development of metastasis, and PCa mortality [22].…”

Section: Prostate-specific Antigen and Prostate-specific Antigen Kinementioning

confidence: 99%

Management of Biochemical Recurrence After Primary Treatment of Prostate Cancer: A Systematic Review of the Literature

et al. 2013

View full text Add to dashboard Cite

Context: Despite excellent cancer control with the treatment of localized prostate cancer (PCa), some men will experience a recurrence of disease. The optimal management of recurrent disease remains uncertain. Objective: To systematically review recent literature regarding management of biochemical recurrence after primary treatment for localized PCa. Evidence acquisition: A comprehensive systematic review of the literature was performed from 2000 to 2012 to identify articles pertaining to management after recurrent PCa. Search terms included prostate cancer recurrence, salvage therapy, radiorecurrent prostate cancer, post HIFU, post cryoablation, postradiation, and postprostatectomy salvage. Studies were selected according to Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines and required to provide a comprehensive description of primary and secondary treatments along with outcomes. Evidence synthesis: The data from 32 original publications were reviewed. The most common option for local salvage therapy after radical prostatectomy (RP) was radiation. Options for local salvage therapy after primary radiation included RP, brachytherapy, and cryotherapy. Different definitions of recurrence and risk profiles among patients make comparative assessment among salvage treatment modalities difficult. Triggers for intervention and factors predicting response to salvage therapy vary. Conclusions: Radiation therapy (RT) after RP can provide durable prostate-specific antigen (PSA) responses in a sizeable percentage of men, especially when given early (ie, PSA <1 ng/ml). Though a few studies suggest improvements in mortality, prospective randomized trials are needed and underway. The role of salvage treatment after RT is less clear.

show abstract

“…1,2 It has been suggested that PSADT may be a surrogate end-point for prostate cancer death. 2 Consequently, PSADT is increasingly being used as a study end-point and by clinicians caring for recurrent prostate cancer patients.…”

Section: Introductionmentioning

confidence: 99%

“…In prior studies of men with biochemical recurrence after primary therapy, many patients did not have calculable PSADT. 1,3 Not only does this highlight the need for alternative prognostic markers for patients with recurrent prostate cancer, this raises the possibility that by limiting analyses to patients with calculable PSADT it may introduce selection bias. Moreover, as evidence grows to support additional therapies for high-risk cases, more patients will receive earlier treatment and even fewer patients will have calculable PSADT in the future.…”

Section: Introductionmentioning

confidence: 99%

Limitations of Prostate Specific Antigen Doubling Time Following Biochemical Recurrence After Radical Prostatectomy: Results From the SEARCH Database

et al. 2008

View full text Add to dashboard Cite

Purpose-PSA doubling time (PSADT) following biochemical recurrence after radical prostatectomy is a powerful predictor of prostate cancer-specific and overall death. To calculate PSADT requires multiple PSA determinations unaltered by secondary therapy separated by sufficient time. Physicians and patients may be unwilling to wait before starting secondary therapy, especially for high-risk recurrences. Hence, those with calculable PSADT may represent a select lower-risk group relative to all men with biochemical recurrence. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Conclusions-Those with calculable PSADT represented a select, lower-risk cohort and the proportion of patients with calculable PSADT declined over time. This highlights the need for alternative markers for men with recurrent prostate cancer as one of our best current markers, PSADT, is only available in a limited number of patients. Methods-We NIH Public Access

show abstract

Risk of Prostate Cancer-Specific Mortality Following Biochemical Recurrence After Radical Prostatectomy

Cited by 183 publications

References 31 publications

Multi-institutional Validation of the CAPRA-S Score to Predict Disease Recurrence and Mortality After Radical Prostatectomy

Multi-institutional Validation of the CAPRA-S Score to Predict Disease Recurrence and Mortality After Radical Prostatectomy

Management of Biochemical Recurrence After Primary Treatment of Prostate Cancer: A Systematic Review of the Literature

Limitations of Prostate Specific Antigen Doubling Time Following Biochemical Recurrence After Radical Prostatectomy: Results From the SEARCH Database

Contact Info

Product

Resources

About